TAG:
ivd/lab informatics
Global IVD Companies Report Second Quarter 2024 Earnings
By Robert Michel | From the Volume XXXI, No. 13 – September 23, 2024 Issue
IN THE SECOND QUARTER OF 2024, in vitro diagnostics (IVD) companies reported solid revenues as well as new tests, analyzers, and automation. Most of the IVD companies boosted diagnostic sales in low single digit amounts. During the earnings calls, financial analysts asked company leade…
Assessing the Clinical Service & Revenue Issues of the LDT Rule
By Robert Michel | From the Volume XXXI, No. 12 – September 3, 2024 Issue
BARRING INTERVENTION BY FEDERAL COURTS OR THE U.S. Congress, clinical labo…
Clarapath Raises $36 Million for Automated Histology Solution
By Robert Michel | From the Volume XXXI, No. 11 – August 12, 2024 Issue
AS THE HISTOLOGY WORKFORCE STRUGGLES TO KEEP UP WITH RISING CASE DEMAND, Clarapath—a Hawt…
What Labs with LDTs Must Do to Comply with FDA’s LDT Rule
By Robert Michel | From the Volume XXXI, No. 10 – July 22, 2024 Issue
CEO SUMMARY: Until the recently filed court challenge to the Food and Drug Administration’s LDT rule succeeds or Congress intervenes with new legislation, those clinical laboratories performing laboratory developed tests (LDTs) must comply with the requirements of the new rule. This com…
UK’s Genomics PLC and MassMutual Offer Free Genetic Testing to Members
By Robert Michel | From the Volume XXXI, No. 9 – July 1, 2024 Issue
CONSUMER-DRIVEN HEALTHCARE PAIRED WITH A FOCUS ON PREVENTATIVE MEDICINE has given birth…
What if Congress Chooses to Pass an LDT-Specific Law?
By Robert Michel | From the Volume XXXI, No. 8 – June 10, 2024 Issue
CONGRESS HAS YET TO SPEAK SPECIFICALLY ON THE ISSUE of regulating laboratory developed test…
Labcorp, Quest Issue Q1 Earnings, Offer Comments on FDA’s LDT Rule
By Robert Michel | From the Volume XXXI, No. 7 – May 20, 2024 Issue
BOTH LABCORP, BURLINGTON, N.C., AND QUEST DIAGNOSTICS, SECAUCU…
Payer Contracts with Labs: Getting the Contract Is Just the Start
By Virchow | From the Volume XXXI, No. 6 – April 29, 2024 Issue
…
FDA Issues Memo to Reclassify Many High Risk IVD Assays
By Robert Michel | From the Volume XXXI, No. 5 – April 8, 2024 Issue
WAS IT AN EXPECTED FLOOD OF APPLICATIONS TO REVIEW laboratory de…
Is Mobile Phlebotomy a Timely Service to Offer Health Plans?
By Virchow | From the Volume XXXI, No. 4 – March 18, 2024 Issue
…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized